WASHINGTON — Baxter International Inc. has found signs of a possible contaminant in the recalled blood thinner heparin that caused hundreds of serious side effects in the United States, which further points suspicion at ingredient suppliers in China.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
Baxter stressed Wednesday that neither it nor government investigators know yet what is to blame for the reactions.
But Baxter's high-tech testing of batches of the problem drug found signs of what it called a "heparin-like molecule," a substance not found in batches of problem-free heparin.
Baxter said that means the problems may have originated with Chinese suppliers of heparin's main ingredient, which is derived from pig intestines.
The U.S. Food and Drug Administration found quality-control problems last week at a Chinese supply factory. The agency had not inspected the factory earlier, which was a violation of its own rules, because of a mix-up with the company's name.
That factory in turn receives crude heparin from numerous smaller suppliers, or "workshops," complicating the search for answers.
Heparin injections are used to prevent blood clotting mostly in patients undergoing dialysis or heart surgery. Baxter, which provides about half the nation's supply, halted production last month after its brand was linked to hundreds of reports of allergic-style reactions, including vomiting, nausea and difficulty breathing.
The FDA last week said four deaths have been associated with the recalled Baxter product, among 21 reports of deaths among patients taking heparin from any manufacturer.
Baxter said Wednesday that FDA inspectors had found no problems at its New Jersey factory that conducts the last steps in heparin production.
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.